

# Doruk Erkan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/463495/publications.pdf>

Version: 2024-02-01

84  
papers

4,653  
citations

136950

32  
h-index

102487

66  
g-index

89  
all docs

89  
docs citations

89  
times ranked

3628  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 2010-2021.   | 27.0 | 503       |
| 2  | Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibodyâ€“positive individuals. <i>Arthritis and Rheumatism</i> , 2007, 56, 2382-2391. | 6.7  | 364       |
| 3  | 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.  | 5.8  | 290       |
| 4  | Estimated Frequency of Antiphospholipid Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature. <i>Arthritis Care and Research</i> , 2013, 65, 1869-1873.          | 3.4  | 275       |
| 5  | Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. <i>Autoimmunity Reviews</i> , 2016, 15, 1120-1124.  | 5.8  | 211       |
| 6  | Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.            | 3.8  | 211       |
| 7  | Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.   | 8.0  | 203       |
| 8  | High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. <i>Arthritis and Rheumatism</i> , 2001, 44, 1466-1467.  | 6.7  | 187       |
| 9  | Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.   | 5.8  | 166       |
| 10 | Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms. <i>Autoimmunity Reviews</i> , 2010, 10, 74-79.   | 5.8  | 152       |
| 11 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , 2016, 3, 75-84.   | 0.6  | 141       |
| 12 | The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2028-2033.   | 0.9  | 124       |
| 13 | Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity. <i>Cell Host and Microbe</i> , 2019, 26, 100-113.e8.  | 11.0 | 109       |
| 14 | A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1176-1180.  | 0.9  | 106       |
| 15 | Catastrophic antiphospholipid syndrome: Where do we stand?. <i>Arthritis and Rheumatism</i> , 2003, 48, 3320-3327.  | 6.7  | 100       |
| 16 | 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.   | 1.6  | 80        |
| 17 | The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.   | 3.4  | 79        |
| 18 | Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. <i>Journal of Rheumatology</i> , 2002, 29, 843-9.  | 2.0  | 77        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , 2018, 57, 1264-1270.  | 1.9  | 70        |
| 20 | Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.  | 3.4  | 60        |
| 21 | New approaches for managing antiphospholipid syndrome. <i>Nature Reviews Rheumatology</i> , 2009, 5, 160-170.  | 8.0  | 58        |
| 22 | How I treat catastrophic thrombotic syndromes. <i>Blood</i> , 2015, 126, 1285-1293.  | 1.4  | 58        |
| 23 | Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 1289-1290.  | 27.0 | 51        |
| 24 | Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 98-103.  | 5.8  | 50        |
| 25 | Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2017, 16, 576-586.   | 5.8  | 48        |
| 26 | What is antiphospholipid syndrome?. <i>Current Rheumatology Reports</i> , 2004, 6, 451-457.  | 4.7  | 42        |
| 27 | Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. <i>Blood Advances</i> , 2017, 1, 2320-2324.   | 5.2  | 40        |
| 28 | Reality Check on Antiphospholipid Antibodies in COVID-19 Associated Coagulopathy. <i>Arthritis and Rheumatology</i> , 2021, 73, 173-174.   | 5.6  | 39        |
| 29 | The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome. <i>Turkish Journal of Haematology</i> , 2016, 33, 1-7.   | 0.5  | 38        |
| 30 | The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141. | 3.4  | 37        |
| 31 | Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 102395.   | 5.8  | 35        |
| 32 | Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the CAPS Registry. <i>Autoimmunity Reviews</i> , 2022, 21, 103055.  | 5.8  | 34        |
| 33 | New Treatments for Antiphospholipid Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 129-148.   | 1.9  | 32        |
| 34 | Patients with overlap autoimmune disease differ from those with 'pure' disease. <i>Lupus Science and Medicine</i> , 2015, 2, e000084-e000084.  | 2.7  | 28        |
| 35 | Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.   | 1.6  | 28        |
| 36 | 16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1594-1600.  | 1.6  | 26        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2006, 18, 242-248.   | 4.3  | 25        |
| 38 | Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. <i>Arthritis and Rheumatism</i> , 2002, 47, 285-290.                                   | 6.7  | 24        |
| 39 | Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2274-2286. | 3.8  | 24        |
| 40 | Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease. <i>Annual Review of Medicine</i> , 2017, 68, 287-296.  | 12.2 | 23        |
| 41 | Treatment of antiphospholipid syndrome beyond anticoagulation. <i>Clinical Immunology</i> , 2019, 206, 53-62.  | 3.2  | 23        |
| 42 | Is there a role for immunosuppression in antiphospholipid syndrome?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 426-432.   | 2.5  | 22        |
| 43 | COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiONal Networking (APS ACTION). <i>Lupus</i> , 2021, 30, 2276-2285.    | 1.6  | 21        |
| 44 | Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2019, 21, 56.   | 4.7  | 20        |
| 45 | Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. <i>Pathophysiology</i> , 2011, 18, 93-102.  | 2.2  | 19        |
| 46 | Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.   | 2.0  | 19        |
| 47 | Defibrotide Inhibits Antiphospholipid Antibody-Mediated Neutrophil Extracellular Trap Formation and Venous Thrombosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 902-907.  | 5.6  | 19        |
| 48 | A critical analysis of 57 cases of Hughes-Stovin syndrome (HSS). A report by the HSS International Study Group (HSSISG). <i>International Journal of Cardiology</i> , 2021, 331, 221-229.  | 1.7  | 18        |
| 49 | The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: A review of the literature and management strategies. <i>Current Rheumatology Reports</i> , 2002, 4, 379-386.         | 4.7  | 17        |
| 50 | New insights into pregnancy-related complications in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2003, 5, 357-363.   | 4.7  | 16        |
| 51 | Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?. <i>Current Rheumatology Reports</i> , 2018, 20, 66.   | 4.7  | 16        |
| 52 | A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis. <i>Pathobiology</i> , 2021, 88, 28-36.   | 3.8  | 15        |
| 53 | Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. <i>European Journal of Rheumatology</i> , 2018, 5, 92-95.  | 0.6  | 14        |
| 54 | How much warfarin is enough in APS related thrombosis?. <i>Thrombosis Research</i> , 2004, 114, 435-442.   | 1.7  | 13        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.   | 1.7 | 13        |
| 56 | Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 102913.  | 5.8 | 13        |
| 57 | Lepromatous Leprosy Mimicking Systemic Lupus Erythematosus. <i>HSS Journal</i> , 2014, 10, 286-291.  | 1.7 | 12        |
| 58 | AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. <i>Current Rheumatology Reports</i> , 2016, 18, 64.   | 4.7 | 12        |
| 59 | Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1209-1216.  | 3.4 | 11        |
| 60 | Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080. | 3.8 | 9         |
| 61 | Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021, 23, 45.  | 4.7 | 9         |
| 62 | 16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2021, 30, 1314-1326.  | 1.6 | 9         |
| 63 | Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guide—a report by the HSS International Study Group. <i>Clinical Rheumatology</i> , 2021, 40, 4993-5008.   | 2.2 | 9         |
| 64 | Systemic Lupus Erythematosus Associated with Rowell's Syndrome. <i>HSS Journal</i> , 2013, 9, 289-292.   | 1.7 | 8         |
| 65 | Elevated Levels of Cytokines and Chemokines in Patients with Antiphospholipid (aPL) Antibodies.. <i>Blood</i> , 2009, 114, 5062-5062.  | 1.4 | 6         |
| 66 | The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. <i>Journal of Rheumatology</i> , 2002, 29, 2658-9.  | 2.0 | 6         |
| 67 | Comment on: "The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome". <i>Thrombosis Research</i> , 2017, 157, 82-83.  | 1.7 | 5         |
| 68 | Variants in chondroitin sulfate metabolism genes in thrombotic storm. <i>Thrombosis Research</i> , 2018, 161, 43-51.   | 1.7 | 5         |
| 69 | Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome. <i>Blood</i> , 2016, 128, 4983-4983.   | 1.4 | 5         |
| 70 | The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the "Catastrophic antiphospholipid syndrome registry". <i>Lupus</i> , 2022, 31, 1218-1225.  | 1.6 | 4         |
| 71 | Antiphospholipid syndrome research needs more collaboration. <i>Nature Reviews Rheumatology</i> , 2014, 10, 266-267.   | 8.0 | 2         |
| 72 | Rapidly Progressive Cardiac Failure Due to Giant Cell Myocarditis. <i>HSS Journal</i> , 2015, 11, 182-186.   | 1.7 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Immunoglobulin G4-related Aortitis. HSS Journal, 2017, 13, 307-312.  | 1.7 | 2         |
| 74 | A106: Rituximab Use in Pediatric Antiphospholipid Antibody Positive Patients. Arthritis and Rheumatology, 2014, 66, S142-S142.   | 5.6 | 1         |
| 75 | Mitral Valve Vegetation in Antiphospholipid Syndrome. Arthritis and Rheumatology, 2016, 68, 1300-1300.   | 5.6 | 1         |
| 76 | High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. , 2001, 44, 1466.  |     | 1         |
| 77 | Impact of antiphospholipid syndrome eBook on medical students'™ improvement of knowledge: An international randomized controlled study. European Journal of Rheumatology, 2019, 6, 207-211.  | 0.6 | 1         |
| 78 | Rare Manifestation of Granulomatosis With Polyangiitis. Clinical Advances in Periodontics, 2013, 3, 45-50.   | 0.7 | 0         |
| 79 | Miscellaneous inflammatory musculoskeletal conditions: Always a diagnostic and therapeutic challenge. Best Practice and Research in Clinical Rheumatology, 2016, 30, 221.  | 3.3 | 0         |
| 80 | Recurrent Complement-Mediated Thrombotic Microangiopathy in a Patient with Systemic Lupus Erythematosus. HSS Journal, 2020, 16, 507-514.   | 1.7 | 0         |
| 81 | Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm. Blood, 2011, 118, 1229-1229.  | 1.4 | 0         |
| 82 | Recurrent Thrombosis in Patients with Antiphospholipid Antibodies and Arterial Thrombosis Treated with Antiplatelets and/or Anticoagulant Therapy. Blood, 2016, 128, 86-86.  | 1.4 | 0         |
| 83 | Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. Advances in Rheumatology, 2021, 61, 64. | 1.7 | 0         |
| 84 | 1504â€¦The influence of dietary resistant starch content on the gut microbiota of patients with systemic lupus erythematosus and antiphospholipid syndrome. , 2021, , .  |     | 0         |